Medtronic plc reported strong financial results for the second quarter of fiscal year 2026, with revenue of $9.0 billion and GAAP diluted EPS of $1.07.
The company experienced significant growth in its Cardiac Ablation Solutions segment, with revenue increasing by 71%, driven by the pulsed field ablation (PFA) portfolio.
Key highlights included exceeding revenue guidance, strong cardiovascular revenue growth, and receiving favorable coverage policies for key procedures in the U.S.
Revenue Growth
Revenue reached $9.0 billion, a 6.6% increase, and exceeded the guidance midpoint by 75 basis points.
Cardiac Ablation Solutions
Revenue in this segment surged by 71%, particularly in the U.S., propelled by the success of the pulsed field ablation (PFA) portfolio.
Guidance Update
The company raised its FY26 guidance with expected organic revenue growth of 5.5% and adjusted EPS in the range of $5.62 to $5.66.
- Medtronic's strong financial performance in Q2 signifies robust market demand and successful execution across its business segments.
- The company's strategic focus on key growth drivers like PFA franchise, robotic-assisted surgery, and innovative therapies positions it for accelerated revenue growth in the future.
Medtronic's Q2 results demonstrate resilience and growth potential, supported by successful product launches and favorable market conditions. The raised guidance reflects confidence in sustained performance and innovation.